Rafferty Asset Management LLC Has $3.16 Million Holdings in Intellia Therapeutics, Inc. $NTLA

Rafferty Asset Management LLC increased its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 42.2% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 183,091 shares of the company’s stock after buying an additional 54,298 shares during the period. Rafferty Asset Management LLC’s holdings in Intellia Therapeutics were worth $3,162,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Headlands Technologies LLC acquired a new stake in shares of Intellia Therapeutics in the second quarter valued at about $26,000. Blue Bell Private Wealth Management LLC bought a new stake in Intellia Therapeutics during the 3rd quarter valued at approximately $30,000. Newbridge Financial Services Group Inc. acquired a new stake in Intellia Therapeutics in the 2nd quarter valued at approximately $52,000. Federated Hermes Inc. increased its position in Intellia Therapeutics by 39.7% in the 3rd quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock worth $56,000 after buying an additional 927 shares during the period. Finally, Johnson Financial Group Inc. lifted its holdings in shares of Intellia Therapeutics by 24.8% during the second quarter. Johnson Financial Group Inc. now owns 6,988 shares of the company’s stock worth $66,000 after buying an additional 1,388 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

NTLA has been the topic of a number of research reports. Leerink Partners boosted their target price on shares of Intellia Therapeutics from $27.00 to $29.00 and gave the stock an “outperform” rating in a research report on Tuesday. Oppenheimer set a $27.00 price target on shares of Intellia Therapeutics in a research report on Friday, November 7th. Brookline Capital Acquisition reaffirmed a “buy” rating on shares of Intellia Therapeutics in a research report on Tuesday. William Blair raised Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Monday. Finally, Royal Bank Of Canada boosted their price target on Intellia Therapeutics from $9.00 to $15.00 and gave the company a “sector perform” rating in a research note on Tuesday. Eleven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Intellia Therapeutics has a consensus rating of “Hold” and an average target price of $19.59.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $13.82 on Thursday. The company has a 50-day moving average of $12.17 and a 200-day moving average of $13.10. Intellia Therapeutics, Inc. has a 52 week low of $5.90 and a 52 week high of $28.25. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of -3.61 and a beta of 2.10.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.16. The firm had revenue of $23.02 million during the quarter, compared to analyst estimates of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The company’s quarterly revenue was up 78.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.27) earnings per share. Sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Key Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds / allows second in‑human trial to resume, removing a major regulatory overhang and clearing Intellia to restart an important gene‑editing program. Read More. Read More.
• Positive Sentiment: Multiple analyst upgrades and target increases (JonesTrading to Buy, Leerink & HC Wainwright bumping targets, William Blair upgrade to Outperform) have supported sentiment and likely drove buying interest. JonesTrading set a $29 PT; HC Wainwright raised its PT to $30. Read More. Read More.
• Positive Sentiment: Intellia presented longer‑term clinical data for lonvoguran (lonvo‑z) at AAAAI showing multi‑year follow‑up after a one‑time dose — reinforces the durability narrative for a key therapeutic candidate. Read More.
• Positive Sentiment: High‑profile investor interest: Cathie Wood’s Ark (coverage piece) noted buying activity in beaten‑up growth names, including Intellia — a potential source of additional demand from momentum/growth investors. Read More.
• Neutral Sentiment: Other broker moves mixed: RBC, Wells Fargo and others nudged targets modestly higher (to ~$15), while Canaccord cut its target from $54 to $48 — consensus remains wide, reflecting varying views on timelines and commercialization risk. Read More.
• Negative Sentiment: HC Wainwright trimmed near‑term EPS estimates across several 2026 quarters and lowered full‑year forecasts slightly even while maintaining a Buy and a $30 PT — a reminder analysts expect continued cash burn and negative earnings into 2026. This raises execution risk and could limit multiple expansion. Read More.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, EVP James Basta sold 10,397 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $95,756.37. Following the sale, the executive vice president directly owned 101,528 shares in the company, valued at $935,072.88. This represents a 9.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO John M. Leonard sold 34,146 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $314,484.66. Following the transaction, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. This represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 53,051 shares of company stock valued at $488,600. Corporate insiders own 3.10% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.